QL1209
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for QL1209, covering 2024-04-19 to 2024-04-19. Get the full timeline:
Most recent: Clinical Trial Update: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. [Phase 3]